The overall positive PD-L1 expression was 66.9% and the negative PD-L1 expression in the tumor was significantly associated with disease recurrence and cancer-specific mortality after adjusting for pathologic tumor stage, grade, lymph node involvement, and lymphovascular invasion. This evidence concerns the gene CD274 and neoplasm.